505 related articles for article (PubMed ID: 22037215)
21. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
Yang F; Qian XJ; Qin W; Deng R; Wu XQ; Qin J; Feng GK; Zhu XF
PLoS One; 2013; 8(3):e59879. PubMed ID: 23533654
[TBL] [Abstract][Full Text] [Related]
22. Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors.
Chanal M; Chevallier P; Raverot V; Fonteneau G; Lucia K; Monteserin Garcia JL; Rachwan A; Jouanneau E; Trouillas J; Honnorat J; Auger C; Theodoropoulou M; Raverot G
Mol Cancer Ther; 2016 Jun; 15(6):1261-70. PubMed ID: 26983879
[TBL] [Abstract][Full Text] [Related]
23. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
[TBL] [Abstract][Full Text] [Related]
24. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
[TBL] [Abstract][Full Text] [Related]
25. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.
Maira SM; Stauffer F; Brueggen J; Furet P; Schnell C; Fritsch C; Brachmann S; Chène P; De Pover A; Schoemaker K; Fabbro D; Gabriel D; Simonen M; Murphy L; Finan P; Sellers W; García-Echeverría C
Mol Cancer Ther; 2008 Jul; 7(7):1851-63. PubMed ID: 18606717
[TBL] [Abstract][Full Text] [Related]
26. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
Kanteti R; Dhanasingh I; Kawada I; Lennon FE; Arif Q; Bueno R; Hasina R; Husain AN; Vigneswaran W; Seiwert T; Kindler HL; Salgia R
PLoS One; 2014; 9(9):e105919. PubMed ID: 25221930
[TBL] [Abstract][Full Text] [Related]
27. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
28. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
[TBL] [Abstract][Full Text] [Related]
29. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.
Schnell CR; Stauffer F; Allegrini PR; O'Reilly T; McSheehy PM; Dartois C; Stumm M; Cozens R; Littlewood-Evans A; García-Echeverría C; Maira SM
Cancer Res; 2008 Aug; 68(16):6598-607. PubMed ID: 18701483
[TBL] [Abstract][Full Text] [Related]
30. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
[TBL] [Abstract][Full Text] [Related]
31. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Husu EN; Pitsillides C; Vesole S; Azab AK; Azab F; Melhem M; Ngo HT; Quang P; Maiso P; Runnels J; Liang MC; Wong KK; Lin C; Ghobrial IM
Blood; 2010 Jan; 115(3):559-69. PubMed ID: 19965685
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
33. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
34. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.
Lin A; Piao HL; Zhuang L; Sarbassov dos D; Ma L; Gan B
Cancer Res; 2014 Mar; 74(6):1682-93. PubMed ID: 24448243
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
36. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.
Aziz SA; Jilaveanu LB; Zito C; Camp RL; Rimm DL; Conrad P; Kluger HM
Clin Cancer Res; 2010 Dec; 16(24):6029-39. PubMed ID: 21169255
[TBL] [Abstract][Full Text] [Related]
37. PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.
Babichev Y; Kabaroff L; Datti A; Uehling D; Isaac M; Al-Awar R; Prakesch M; Sun RX; Boutros PC; Venier R; Dickson BC; Gladdy RA
J Transl Med; 2016 Mar; 14():67. PubMed ID: 26952093
[TBL] [Abstract][Full Text] [Related]
38. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.
Seo BR; Min KJ; Cho IJ; Kim SC; Kwon TK
PLoS One; 2014; 9(4):e95588. PubMed ID: 24743574
[TBL] [Abstract][Full Text] [Related]
39. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.
Roper J; Richardson MP; Wang WV; Richard LG; Chen W; Coffee EM; Sinnamon MJ; Lee L; Chen PC; Bronson RT; Martin ES; Hung KE
PLoS One; 2011; 6(9):e25132. PubMed ID: 21966435
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
